2023
Brain, D. (2023, June 21). Investigating the impact of, novel, therapeutic delivery systems on immunological responses - determination of short, and long-term, exposure effects.
2022
Plant-Hately, A. J., Eryilmaz, B., David, C. A. W., Brain, D. E., Heaton, B. J., Perrie, Y., & Liptrott, N. J. (2022). Exposure of the Basophilic Cell Line KU812 to Liposomes Reveals Activation Profiles Associated with Potential Anaphylactic Responses Linked to Physico-Chemical Characteristics. PHARMACEUTICS, 14(11). doi:10.3390/pharmaceutics14112470DOI: 10.3390/pharmaceutics14112470
Heaton, B. J., Jensen, R. L., Line, J., David, C. A. W., Brain, D. E., Chadwick, A. E., & Liptrott, N. J. (2022). Exposure of human immune cells, to the antiretrovirals efavirenz and lopinavir, leads to lower glucose uptake and altered bioenergetic cell profiles through interactions with SLC2A1. BIOMEDICINE & PHARMACOTHERAPY, 150. doi:10.1016/j.biopha.2022.112999DOI: 10.1016/j.biopha.2022.112999
2021
Brain, D., Plant-Hately, A., Heaton, B., Arshad, U., David, C., Hedrich, C., . . . Liptrott, N. J. (2021). Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19. ADVANCED DRUG DELIVERY REVIEWS, 178. doi:10.1016/j.addr.2021.113848DOI: 10.1016/j.addr.2021.113848
